Malaria: Drugs

Ministry of Defence written question – answered at on 8 July 2019.

Alert me about debates like this

Photo of The Countess of Mar The Countess of Mar Deputy Chairman of Committees, Deputy Speaker (Lords)

To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General’s 2016–17 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events.

Photo of Earl Howe Earl Howe The Minister of State, Ministry of Defence, Deputy Leader of the House of Lords

Adverse events are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow card scheme and can be undertaken by a healthcare professional or the individual experiencing the adverse effect. The demographics required by the Yellow card scheme do not include the occupation of the subject, so military personnel are not uniquely identified.

The aims of the "713/MoDREC/15" study do not include assessing whether individuals or their healthcare professional reported side effects to the MHRA or to follow-up whether any person experiencing side effects required any form of treatment, including an assessment of whether suitable treatment was available. Data collated in the study is self-reported by individuals and any symptoms reported may not necessarily be related to the anti-malarial taken.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.